Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Outlook Therapeutics Inc (NASDAQ: OTLK) was $1.83 for the day, down -1.61% from the previous closing price of $1.86. In other words, the price has decreased by -$1.61 from its previous closing price. On the day, 2.85 million shares were traded. OTLK stock price reached its highest trading level at $1.875 during the session, while it also had its lowest trading level at $1.77.
Ratios:
Our analysis of OTLK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.67.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 117329352 and an Enterprise Value of 139440960. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.83. Its current Enterprise Value per Revenue stands at 98.647 whereas that against EBITDA is -2.083.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.17, which has changed by -0.08955222 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $3.39, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is 10.06%, while the 200-Day Moving Average is calculated to be 12.72%.
Shares Statistics:
OTLK traded an average of 3.32M shares per day over the past three months and 3990480 shares per day over the past ten days. A total of 43.48M shares are outstanding, with a floating share count of 29.09M. Insiders hold about 34.52% of the company’s shares, while institutions hold 9.11% stake in the company. Shares short for OTLK as of 1765756800 were 3082849 with a Short Ratio of 0.93, compared to 1763078400 on 4060839. Therefore, it implies a Short% of Shares Outstanding of 3082849 and a Short% of Float of 6.7.
Earnings Estimates
The market rating of Outlook Therapeutics Inc (OTLK) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.28 and -$1.67 for the fiscal current year, implying an average EPS of -$0.95. EPS for the following year is -$0.59, with 4.0 analysts recommending between $0.02 and -$1.36.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $2M. There is a high estimate of $2M for the next quarter, whereas the lowest estimate is $2M. A total of 2 analysts have provided revenue estimates for OTLK’s current fiscal year. The highest revenue estimate was $14M, while the lowest revenue estimate was $9.6M, resulting in an average revenue estimate of $11.8M. In the same quarter a year ago, actual revenue was $1.41MBased on 4 analysts’ estimates, the company’s revenue will be $35.8M in the next fiscal year. The high estimate is $53.9M and the low estimate is $19.31M.
